(Q38016957)

27 August 2017

title

Catumaxomab: in malignant ascites (English)

1 reference

27 August 2017

James E Frampton

1

1 reference

27 August 2017

publication date

1 July 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

72

1 reference

27 August 2017

issue

10

1 reference

27 August 2017

page(s)

1399-1410

1 reference

https://api.crossref.org/works/10.2165%2F11209040-000000000-00000

27 August 2017

1 reference

Pattern and prognostic factors in patients with malignant ascites: a retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209040-000000000-00000

Malignant ascites: a 2-year review from a teaching hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209040-000000000-00000

Treatment of malignant ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209040-000000000-00000

Intractable malignant ascites: an alternative management option.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209040-000000000-00000

The current and future management of malignant ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209040-000000000-00000

Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209040-000000000-00000

Epithelial cell adhesion molecule expression (CD326) in cancer: a short review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209040-000000000-00000

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209040-000000000-00000

Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209040-000000000-00000

Catumaxomab: clinical development and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209040-000000000-00000

Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209040-000000000-00000

Structural and functional characterization of the trifunctional antibody catumaxomab

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209040-000000000-00000

Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209040-000000000-00000

Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209040-000000000-00000

The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209040-000000000-00000

Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209040-000000000-00000

Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209040-000000000-00000

Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209040-000000000-00000

Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3)

21 January 2018

1 reference

12 December 2020

Current and future options in the treatment of malignant ascites in ovarian cancer.

1 reference

12 December 2020

Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody

1 reference

12 December 2020

Palliative treatment of malignant ascites: profile of catumaxomab

1 reference

12 December 2020

Palliative treatment of malignant ascites #177

1 reference

12 December 2020

Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes

1 reference

12 December 2020

Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing

1 reference

12 December 2020

10.2165/11209040-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1036931797

0 references

Fatcat ID

release_54qtrvrhxveyzgruhlkji25gp4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/54qtrvrhxveyzgruhlkji25gp4

24 November 2022

mapped directly with Wikidata item

1 reference